The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBenchmark Holdings Regulatory News (BMK)

Share Price Information for Benchmark Holdings (BMK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 43.10
Bid: 43.10
Ask: 46.90
Change: 1.30 (2.97%)
Spread: 3.80 (8.817%)
Open: 43.10
High: 43.10
Low: 43.10
Prev. Close: 43.70
BMK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Trading Update and Notice of Results

26 May 2016 07:00

RNS Number : 3431Z
Benchmark Holdings PLC
26 May 2016
 

26 May 2016

Benchmark Holdings plc("Benchmark", the "Company" or the "Group")

Trading Update and Notice of Results

· Trading in line with management's expectations

· INVE integration progressing well with first operational synergies realised

· Braintree manufacturing facility expected to enter commissioning by September

· Encouraging progress in development pipeline

Benchmark, the biotechnology and food chain sustainability business, announces that Group performance for the six months to 31 March 2016 was in line with management's expectations.

The integration of INVE is progressing well, with operational synergies being realised through utilisation of INVE's distribution network to support the launch of the first of our new aquaculture vaccines from the Animal Health pipeline, and use of INVE's products in the Breeding and Genetics division's lumpfish programme. The Advanced Animal Nutrition division performed slightly ahead of management's expectations.

The Animal Health, Sustainability Science and Technical Publishing divisions all performed in line with management's expectations.

Benchmark's development pipeline is progressing well, with a new aquaculture vaccine targeted at the Mediterranean region expected to be commercialised this year. This vaccine was developed, is manufactured and will be distributed entirely by the Group. New vaccine manufacturing facilities at Braintree and aquaculture trials facilities at Ardtoe are coming online to provide the vital infrastructure to deliver the Group's development portfolio.

In line with guidance provided at year end, the Breeding and Genetics division has had a difficult first half as a result of the closure of the Chilean border to Icelandic salmon eggs. Recovery was slower than anticipated, aggravated by lower stocking in the Chilean industry in response to environmental challenges, with sales significantly impacted. The underperformance in this division was balanced by positive performance elsewhere in the Group.

El Niño has had an impact on the climate in South East Asia and Latin America and the algal bloom in Chile has reduced total salmon biomass across the Chilean industry. Climatic factors can have a significant influence on sales of aquaculture health products, salmon eggs or advanced nutrition, and while management continues to monitor the situation, the Company remains on track for the full year.

The long term drivers of growth in the Company's sectors are clearly positive. The Group's targeted expansion now allows Benchmark to offer an integrated package of products and services to its customers, and key account management is being introduced to strengthen the Group's ability to exploit the significant opportunities in the markets it serves.

Benchmark expects to announce its interim results for the six months to 31 March 2016 on Tuesday, 28 June 2016.

Commenting on trading, Benchmark's Chief Executive Officer, Malcolm Pye, said:

"We have had a busy first half and made significant progress as we continue to develop Benchmark into a group that comprehensively serves the needs of our customers. The quality of our divisional management teams has been evident during the integration of INVE as they continue their work to realise synergies available to the enlarged Group.

"Our strategy of diversification is showing its value and importance, with half year performance in line with our expectations, despite the disruption caused by the border situation in Chile.

"Having completed the process of creating a scalable group structure, the outlook for Benchmark is extremely promising. The markets we serve are not transitory, but are the fundamental building blocks of a sustainable food chain. With all of the pressures being placed upon these industries, we are an increasingly important partner to our customers. Against this backdrop, we will continue our work to achieve our long term potential and create value, by launching the new products our customers urgently need and growing sales."

 

-Ends-

 

For further information, please contact:

 

Benchmark Holdings plc

Tel: 020 7920 3150

Malcolm Pye, CEO

 

Roland Bonney, COO

Rachel Aninakwah, Communications

Cenkos Securities PLC

Tel: 020 7397 8900

Ivonne Cantu / Stephen Keys (NOMAD)

Russell Kerr (Sales)

Tavistock

Tel: 020 7920 3150

Matt Ridsdale / Niall Walsh

 

 

Notes to Editors:

Founded in 2000, Benchmark represents a new model in sustainable business development. Over the last decade it has built a profitable group of companies on the economics of a sustainable food chain. The Company is growing in response to a rapidly increasing demand for sustainable food chains, and in particular for seafood, from both mature and emerging markets.

Benchmark is an ethical company with an explicit policy based on the "3E's" definition of a sustainable business - ethics, environment and economics - which guides its strategy and operations.

The group has five divisions: Animal Health which researches, manufactures and markets medicines and vaccines particularly for aquaculture, Sustainable Science which researches and informs sustainable development in the food industry, Technical Publishing which effects technology transfer through online publishing and education, Breeding and Genetics which comprises a world-leading Salmon and aquaculture breeding business, and Advanced Animal Nutrition which provides cutting edge nutritional products and services to the aquaculture industry. Benchmark operates internationally with offices in England, Scotland, Belgium, Ireland, Norway, Iceland, USA, Brazil, China, Moscow, India, Thailand and Chile. As at 1 May 2016, Benchmark employs 881 people.

For further information on Benchmark please visit www.benchmarkplc.com

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTLFFLIESIEFIR
Date   Source Headline
18th Oct 20217:00 amRNSTrading Statement
30th Sep 20217:00 amRNSTotal Voting Rights
23rd Sep 20217:00 amRNSEnvironmental recognition for CleanTreat®
21st Sep 20217:00 amRNSBlock Listing Six Monthly Return
31st Aug 20217:00 amRNSTotal Voting Rights
25th Aug 20217:00 amRNSEquity Development Investor Webinar
24th Aug 20217:00 amRNSQ3 Results
30th Jul 20217:00 amRNSTotal Voting Rights
15th Jul 20213:00 pmRNSAdoption of MRL for Ectosan Vet in Norway
2nd Jul 20213:20 pmRNSBMK08+CleanTreat and Trading Update
30th Jun 20217:00 amRNSTotal Voting Rights
21st Jun 20214:41 pmRNSSecond Price Monitoring Extn
21st Jun 20214:36 pmRNSPrice Monitoring Extension
2nd Jun 20214:41 pmRNSSecond Price Monitoring Extn
2nd Jun 20214:35 pmRNSPrice Monitoring Extension
28th May 20217:00 amRNSTotal Voting Rights
25th May 20217:00 amRNSDirector Dealings
18th May 20217:00 amRNSSecond Quarter and Interim results
30th Apr 20217:00 amRNSTotal Voting Rights
19th Apr 20217:00 amRNSNotice of Q2 and Interim Results
16th Apr 202111:00 amRNSBMK08+CleanTreat Update
31st Mar 20213:41 pmRNSDirector Dealings
31st Mar 20217:00 amRNSTotal Voting Rights
30th Mar 20217:00 amRNSListing of existing senior secured NOK bond
26th Mar 20218:24 amRNSBMK08+CleanTreat Update
19th Mar 20217:00 amRNSBLOCK LISTING SIX MONTHLY RETURN
26th Feb 202110:52 amRNSTotal Voting Rights
22nd Feb 20217:00 amRNSQ1 Results
9th Feb 202112:43 pmRNSResult of AGM
9th Feb 20217:00 amRNSNotice of Q1 Results
29th Jan 20217:00 amRNSTotal Voting Rights
13th Jan 20217:00 amRNSIssue of Equity
8th Jan 20211:13 pmRNSReplacement: DIRECTOR SHARE OPTIONS
8th Jan 20219:57 amRNSDIRECTOR SHARE OPTIONS
6th Jan 20213:45 pmRNSDirector Dealings
31st Dec 20207:00 amRNSTotal Voting Rights
11th Dec 20205:32 pmRNSPosting of Annual Report and Notice of AGM
2nd Dec 20202:09 pmRNSDirector Dealings
1st Dec 20204:02 pmRNSAnnual Financial Report
1st Dec 202011:30 amRNSDirector Dealings
1st Dec 202010:30 amRNSDirector Dealings
1st Dec 202010:21 amRNSPCA Dealing
30th Nov 20207:00 amRNSTotal Voting Rights
27th Nov 20207:00 amRNSQ4 Results
27th Nov 20207:00 amRNSFull Year Results
18th Nov 20207:00 amRNSDirectorate Change
4th Nov 20207:00 amRNSInvestor Presentation for Retail Investors
30th Oct 20207:00 amRNSTotal Voting Rights
27th Oct 20207:00 amRNSNotice of Results
13th Oct 20202:29 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.